Haldol (Haloperidol)

Injectable haloperidol is often used when rapid control of severe agitation, acute psychosis, or mania is required, or when the patient cannot take oral medication.

Caution is advised for patients with known QT interval prolongation or other cardiac conduction disorders, and ECG monitoring may be recommended.

Typical side effects include drowsiness, dry mouth, blurred vision, constipation, and mild extrapyramidal symptoms such as tremor or rigidity.

The product should be kept in its original packaging, protected from light, and stored at controlled room temperature as specified by the manufacturer.

The safety of haloperidol during pregnancy has not been fully established; clinicians must weigh potential benefits against unknown risks.

Patients should be observed for signs of extrapyramidal reactions, changes in blood pressure, cardiac rhythm abnormalities, and rare but serious conditions like neuroleptic malignant syndrome.

Yes, co‑administration with antibiotics known to prolong QT (e.g., macrolides) should be avoided or closely monitored.

Healthcare providers may consider administering an anticholinergic agent such as benztropine or diphenhydramine to alleviate the symptoms.

Dose adjustments may be necessary for individuals with severe hepatic or renal dysfunction; dosing should be individualized by the prescriber.

The therapeutic effect can last from several hours up to a day, depending on the dose and individual patient metabolism.

Elderly patients, especially those with dementia‑related psychosis, have an increased risk of mortality and should be treated with the lowest effective dose and close monitoring.